Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions
Brain Stem NeoplasmPineal Region NeoplasmRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmRecurrent Visual Pathway GliomaRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System NeoplasmRefractory Visual Pathway Glioma
Interventions
DRUG

Entinostat

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (21)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02780804 - Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter